Group 1 - The US leveraged loan market is under increasing pressure, with the second transaction being withdrawn this week, following a trend of multiple adjustments to attract investors [1] - Mallinckrodt, a pharmaceutical company, has suspended a $1.49 billion loan issuance plan, which was intended to lower borrowing rates by up to 0.75 percentage points [1] - Since August, a total of 8 transactions have been forced to be withdrawn due to declining investor demand for high-risk debt [1] Group 2 - The secondary market prices for US leveraged loans have been declining almost daily over the past two weeks, indicating a growing caution among investors [2] - To support the acquisition financing for MJH Life Sciences, banks completed a leveraged loan sale but had to offer one of the deepest discounts of the year to attract buyers [2] - A group of banks led by Santander is required to retain part of a $2.7 billion financing to support another acquisition, reflecting the challenges in the current market [2]
美国杠杆贷款市场承压 多笔交易被迫撤回
Zhi Tong Cai Jing·2025-10-11 06:33